Life Sciences Health

The Dutch Life Sciences & Health (LSH) sector strives to utilize its potential to the utmost, enabling patients and society to benefit from its excellent position in research and healthcare.

To make a difference the sector focuses on efficacious, cost-effective innovations to generate health and wealth. As a home market, the Netherlands may be small. But as a proving ground and springboard to world markets, the Netherlands may be unparalleled. The Netherlands is the only country which has consistently been among the top three in the total ranking of any European Index the Health Consumer Powerhouse has published since 2005. We possess one of the most concentrated LSH clusters in the world. Our university medical centers are European leaders in clinical research, our Public-Private Partnerships have set an international standard, and our science and education base is world-class.

Overall, this creates a conducive innovation environment in which the Dutch healthcare industry is able to flourish to its full potential.

The Netherlands is the only country which has consistently been among the top three in the
total ranking of any European Index the Health Consumer Powerhouse has published since
2005. We possess one of the most concentrated LSH clusters in the world. Our university medical centers are European leaders in clinical research,
our Public-Private Partnerships have set an international standard, and our science and education base is world-class.
Overall, this creates a conducive innovation environment in which the Dutch healthcare industry is able to flourish to its full potential.

Focus on health and wealth

In 2012 Dutch health care insurers Achmea and Menzis and investment company Life Sciences Partners set up an investment fund for innovation in healthcare, the LSP-Health Economics Fund. The fund of 50 million euros will seek to invest in international technology companies that may contribute to increased health care 

Dutch LSH sector: Summary of cluster performance in 2010 & 2011

In the Life Sciences Outlook 2013, the Dutch LSH cluster was monitored on six key indicators. 

INPUT 2010 2011
Private investments raised 1 280 mln € 1887 mln € 2
Public investments 297 mln € 291 mln €
OUTPUT 2010 2011
Number of products in development 111 122
Total revenue 17,7 bln € 17,8 bln €
SIZE 2010 2011
Number of listed and non-listed companies 329 343
Total FTEs 24385 22732

1) Milestone payments, Venture Capital, Initial Public Offerings, Follow-on Public Offerings and Private Investment in Public Equities
2) Almost 90% of the private investment raised is due to the acquisition of all shares of Crucell by J&J (1687 mln €)

Source: Dutch Life Sciences & Health Outlook 2013 (The Decision Group)

Life Science & Health in the Netherlands

This film shows why the Netherlands is one of the best breeding grounds for life sciences.

Year In Review 2013 LSH Year In Review Magazine